Redeye comments on Initiator Pharma’s announcements earlier today regarding its clinical expansion i...
Nettoomsättningen för det första kvartalet uppgick till 8,2 MEURO (10,9), vilket motsvarade en minsk...
Organic sales decline of 9% y-o-y EBIT margin of 5.
Q1 sales +40% y-o-y, +2% q-o-q, FCF negative Cut '25e-'27e sales by 7% on weaker Q2 outlook Market r...
The MSA (Master Service Agreement) include a first study work order of SEK 4m in sales from late 202...
Luxbright AB (”Luxbright” eller ”Bolaget”) meddelade den 16 maj 2025 att Bolaget mottagit en ny orde...
Soft Q1 earnings driven by gross margin pressure in the US Weaker USD weighs on estimates, given US-...
Redeye comments on Lytix Biopharma’s first quarter review of 2025.
Redeye provides an update following Paxman’s Q1 2025 report.
Portfolio rebalancing and weak market behind PW We lower '25e-'27e EBIT by 31-22% on lower sales We ...
HydrogenPro published the Company’s interim report for the first quarter of 2025 on May 15, 2025.
Redeye provides a brief summary of Elicera’s Q1'25 report.
Voi, som är VNV Globals näst största innehav, kom med en stark Q1-rapport.
Safello’s net sales came in 9% below Redeye Research Estimates (RRe) at SEK194m, growing 1% y/y.
Cantargia har investerat i en stor fas -1 studie med CAN10 för att skaffa ett bra underlag inför näs...
